Format

Send to

Choose Destination
Cell Tissue Res. 2018 May;372(2):287-307. doi: 10.1007/s00441-018-2820-3. Epub 2018 Mar 27.

Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Ritenour LE1,2,3, Randall MP2,3,4, Bosse KR2,3,4, Diskin SJ5,6,7,8,9.

Author information

1
Cell and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
2
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
3
Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
4
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5
Cell and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. diskin@email.chop.edu.
6
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. diskin@email.chop.edu.
7
Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. diskin@email.chop.edu.
8
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. diskin@email.chop.edu.
9
Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. diskin@email.chop.edu.

Abstract

Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer. Approximately 1-2% of neuroblastomas are inherited in an autosomal dominant fashion and a combination of co-morbidity and linkage studies has led to the identification of germline mutations in PHOX2B and ALK as the major genetic contributors to this familial neuroblastoma subset. The genetic basis of "sporadic" neuroblastoma is being studied through a large genome-wide association study (GWAS). These efforts have led to the discovery of many common susceptibility alleles, each with modest effect size, associated with the development and progression of sporadic neuroblastoma. More recently, next-generation sequencing efforts have expanded the list of potential neuroblastoma-predisposing mutations to include rare germline variants with a predicted larger effect size. The evolving characterization of neuroblastoma's genetic basis has led to a deeper understanding of the molecular events driving tumorigenesis, more precise risk stratification and prognostics and novel therapeutic strategies. This review details the contemporary understanding of neuroblastoma's genetic predisposition, including recent advances and discusses ongoing efforts to address gaps in our knowledge regarding this malignancy's complex genetic underpinnings.

KEYWORDS:

Familial neuroblastoma; Genome-wide association studies; Germline; Neuroblastoma susceptibility; Pediatric cancer

PMID:
29589100
PMCID:
PMC6893873
DOI:
10.1007/s00441-018-2820-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center